WARRINGTON, Pa., Nov. 19, 2018 /PRNewswire/ -- The Ott Group is pleased to announce the creation of a new subsidiary,
"This new business gives us the capability to design and develop diagnostics, as well as specialty reagents to meet the growing demands of our customers," said Michael H. Ott, President & CEO of The Ott Group. "The products and services that Ethos provides will be offered through the broad distribution of our sister companies, and it will address a new segment of the industry for us."
In conjunction, Ethos Biosciences has acquired the Exocell product line from Glycadia Pharmaceuticals. Exocell products have served the scientific community for more than 30 years as trusted, easy-to-use diagnostics and reagents. Primarily used in experimental and clinical research of diabetes and associated kidney and vascular diseases, Exocell offers products targeting albumin, glycated albumin, creatinine, nephrin, collagen and hemoglobin, among many others.
"Ethos will continue to provide the excellent products that our customers expect while building our product offerings," said Ryan Ott, President of Ethos Biosciences. "We also look forward to providing custom development of reagents and diagnostic test kits to help our customers meet their research and clinical goals. The expertise of our scientific staff at Ethos is incredible with more than 100 scientific publications and dozens of patent applications. We intend to build upon the legacy of the Exocell brand."
Ethos Biosciences will assume the laboratory and office space of the former Glycadia diagnostic unit at 1880 JFK Boulevard, in Philadelphia.
About The Ott GroupThe Ott Group is a family owned and operated holding company of specialty chemical manufacturing and related companies, which includes Polysciences, Inc., Bangs Laboratories, Inc., Astral Diagnostics, Inc., Creative Consumer Products, Inc., Polysciences GmbH, Polysciences Asia-Pacific, Inc.
View original content:http://www.prnewswire.com/news-releases/the-ott-group-announces-the-creation-of-ethos-biosciences-inc-300752796.html
SOURCE The Ott Group
Subscribe to our Free Newsletters!